Berinert 500 IU lyophilized powder for intravenous injection Images
Generic Name: C1 esterase inhibitor (human)
This medication has been identified as Berinert 500 IU lyophilized powder for intravenous injection. It is supplied by CSL Behring.
Berinert is used in the treatment of Hereditary Angioedema and belongs to the drug class hereditary angioedema agents. Risk cannot be ruled out during pregnancy. Berinert 500 IU lyophilized powder for intravenous injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Berinert
- Generic Name
- C1 esterase inhibitor (human)
- Strength
- 500 IU lyophilized powder for intravenous injection
- Availability
- Prescription only
- Drug Class
- Hereditary angioedema agents
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- CSL Behring
- National Drug Code (NDC)
- 63833-0825
See also:
Kalbitor
Kalbitor is used to treat acute attacks of hereditary angioedema (HAE) in patients 12 years and ...
Orladeyo
Orladeyo (berotralstat) is used to prevent attacks of hereditary angioedema (HAE). Includes ...
Takhzyro
Takhzyro (lanadelumab-flyo) is used to prevent hereditary angioedema (HAE) and reduce symptoms ...
Firazyr
Firazyr is used to treat acute attacks of hereditary angioedema (HAE) in adults. It can be ...
Ruconest
Ruconest is used to treat angioedema attacks in adult and adolescent patients with Hereditary ...
Cinryze
Cinryze (complement C1 esterase inhibitor) is used to prevent attacks of angioedema in people with ...
More about Berinert (C1 esterase inhibitor (human))
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: hereditary angioedema agents
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.